Efficacy and Safety of Sparsentan Compared With Irbesartan in Patients With Primary Focal Segmental Glomerulosclerosis: Randomized, Controlled Trial Design (DUET)
Primary focal segmental glomerulosclerosis (FSGS) is a leading cause of nephrotic syndrome and end-stage renal disease. There are no US Food and Drug Administration−approved therapies for FSGS, and treatment often fails to reduce proteinuria. Endothelin is an important factor in the pathophysiology...
Main Authors: | Radko Komers, Debbie S. Gipson, Peter Nelson, Sharon Adler, Tarak Srivastava, Vimal K. Derebail, Kevin E. Meyers, Pablo Pergola, Meghan E. MacNally, Jennifer L. Hunt, Alvin Shih, Howard Trachtman |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2017-07-01
|
Series: | Kidney International Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2468024917300529 |
Similar Items
-
Efficiency assessment for antihypertensive, hemodynamic, renal effects of adenosine-converting enzyme (ACE) inhibitors and irbesartan and impact on endothelial disfunction in patients with stage II hypertension
by: M. V. Pereviazkina
Published: (2014-08-01) -
Study Design of the Phase 3 Sparsentan Versus Irbesartan (DUPLEX) Study in Patients With Focal Segmental Glomerulosclerosis
by: Radko Komers, et al.
Published: (2020-04-01) -
Dextran-Sulfate Plasma Adsorption Lipoprotein Apheresis in Drug Resistant Primary Focal Segmental Glomerulosclerosis Patients: Results From a Prospective, Multicenter, Single-Arm Intervention Study
by: Rupesh Raina, et al.
Published: (2019-12-01) -
Expression Levels of miR-30c and miR-186 in Adult Patients with Membranous Glomerulonephritis and Focal Segmental Glomerulosclerosis
by: Hejazian SM, et al.
Published: (2020-08-01) -
Prevalence of pulmonary thromboembolism in nephrotic syndrome patients: A systematic review and meta-analysis
by: Abdullah Nasser Leslom, et al.
Published: (2020-01-01)